3/3/2014 7:35:24 AM
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the appointment of Mark P. Carthy to the company's Board of Directors.
"We are very pleased to have Mark join Rexahn’s Board of Directors," said Peter D. Suzdak, Ph.D., Rexahn’s Chief Executive Officer. "Mark’s extensive business and financing experience in the life sciences will be particularly important as we continue the development of our three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) for the treatment of multiple types of cancer.”
Help employers find you! Check out all the jobs and post your resume.
comments powered by